Loading…

Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: A retrospective, multicenter, nonrandomized, open-label study

Abstracts Objectives: The aim of this study was to assess the therapeutic effectiveness of adefovir dipivoxil (ADV), administered in combination with lamivudine (LAM) or as monotherapy, and the rate of resistance to ADV, in hepatitis B e antigen (HBeAg)-negative adult patients with chronic hepatitis...

Full description

Saved in:
Bibliographic Details
Published in:Clinical therapeutics 2008-02, Vol.30 (2), p.317-323
Main Authors: Pellicelli, Adriano M., MD, Barbaro, Giuseppe, MD, Francavilla, Ruggiero, MD, Romano, Mario, MD, Barbarini, Giorgio, MD, Mazzoni, Ettore, MD, Mecenate, Fabrizio, MD, Paffetti, Amerigo, MD, Barlattani, Angelo, MD, Struglia, Carlo, MD, Villani, Roberto, MD, Nauri, Leone, MD, Nosotti, Lorenzo, MD, Armignacco, Orlando, MD, Ferri, Fabrizio, MD, Camporiondo, Maria Pia, MD, Soccorsi, Fabrizio, MD
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstracts Objectives: The aim of this study was to assess the therapeutic effectiveness of adefovir dipivoxil (ADV), administered in combination with lamivudine (LAM) or as monotherapy, and the rate of resistance to ADV, in hepatitis B e antigen (HBeAg)-negative adult patients with chronic hepatitis B virus (HBV) infection and clinical or virologic resistance to LAM. Furthermore, we evaluated in these selected patients the clinical co-variates associated with a sustained virologic response. Methods: Data from adult outpatients aged >18 years with chronic HBV infection and clinical or virologic resistance to LAM were used in this retrospective, multicenter, nonrandomized, open-label study. Patients were selected if they received ADV 10 mg PO QD + LAM 100 mg QD PO or ADV 10 mg PO QD as monotherapy for 24 to 32 months between June 2003 and July 2006. End points were the proportions of patients who achieved virologic response (undetectable HBV-DNA [
ISSN:0149-2918
1879-114X
DOI:10.1016/j.clinthera.2008.02.012